BACKGROUND: Two androgen receptor (AR)-targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). Many patients respond to these agents, but both de novo and acquired resistance are common. The authors characterized resistant phenotypes that emerge after treatment with abiraterone or enzalutamide. METHODS: Patients who received abiraterone or enzalutamide in the course of routine clinical care were consented for serial blood collection. A proprietary system (CellSearch) was used to enumerate and enrich circulating tumor cells (CTCs). RNA-sequencing (RNA-seq) was performed on pools of up to 10 epithelial cell adhesion molecule (EpCAM)-positive/CD45-negative CTCs. The impact of gene expression changes observed in CTCs between patients who responded or were resistant to abiraterone/enzalutamide therapies was further explored in a model cell line system. RESULTS: RNA-seq data from CTCs identified mutations commonly associated with CRPC as well as novel mutations, including several in the ligand-binding domain of AR that could facilitate escape from AR-targeted agents. Ingenuity pathway analysis of differentially regulated genes identified the transforming growth factor b (TGFb) and cyclin D1 (CCND1) signaling pathways as significantly upregulated in drugresistant CTCs. Transfection experiments using enzalutamide-sensitive and enzalutamide-resistant LNCaP cells confirmed the involvement of SMAD family member 3, a key mediator of the TGFb pathway, and of CCND1 in resistance to enzalutamide treatment. CON-CLUSIONS: The current results indicate that RNA-seq of CTCs representing abiraterone and enzalutamide sensitive and resistant states can identify potential mechanisms of resistance. Therapies targeting the downstream signaling mediated by SMAD family member 3 (SMAD3) and CCND1, such as cyclin-dependent kinase 4/cyclin-dependent kinase 6 inhibitors, could provide new therapeutic options for the treatment of antiandrogen-resistant disease.
INTRODUCTION
Prostate cancer represents the most common malignancy in men. 1 A proportion of patients ultimately develop incurable metastatic disease. The initial treatment paradigm for metastatic disease relies heavily on the finding that prostate cancer is driven by androgen-mediated signaling, 2,3 so androgen-deprivation therapy (ADT) remains the standard of care. 4, 5 Although ADT is effective at controlling disease for several years, patients inevitably progress to castration-resistant prostate cancer (CRPC). Despite the introduction of several new treatment options, including abiraterone acetate and enzalutamide for metastatic CRPC (mCRPC), the disease state remains lethal. To improve outcomes, it is paramount to understand the biologic characteristics of the resistant disease that emerges in response to novel therapies. Unfortunately, repeat biopsy samples are difficult to obtain and may not reflect the full complexity of the disease. Circulating tumor cells (CTCs) provide a powerful alternative to biopsies for determining the molecular characteristics of cells that emerge after development of resistance. The presence of 5 CTCs measured with the CellSearch system (Veridex, LLC, Raritan, NJ) is associated with poor survival in patients with mCRPC. Furthermore, increases in the number of CTCs after treatment with androgen receptor (AR)-targeted agents (ie, abiraterone acetate plus prednisone or enzalutamide) appear to be indicative of a lack of clinical response. 6 Such an association with clinical outcome suggests that CTCs play an important role in the metastatic process. Moreover, detailed molecular characterization of CTCs at various points of the disease course may be useful in understanding the evolution of tumors and could aid in the selection of optimal therapeutic regimens. To better characterize resistant phenotypes that emerge after treatment with abiraterone acetate plus prednisone or enzalutamide, we collected blood from patients with mCRPC before they started either drug regimen and at various time points during therapy. To obtain molecular profiles of CTCs, we isolated single CTCs using CellSearch platform enrichment and performed RNA sequencing of pools of a small number of cells, which enabled us to track changes in the molecular characteristics of CRPC upon progression. We identified novel mutations in the ligand-binding domain of AR that could facilitate escape from AR-targeted agents. Our analysis also demonstrated that transforming growth factor b (TGFb)/SMAD family member 3 (SMAD3) and cyclin D1 (CCND1) signaling play important roles in driving oncogenic transformation after AR-targeted treatment.
MATERIALS AND METHODS

Patient Selection
To be eligible for this study, patients must have had a cytologically or pathologically verified diagnosis of prostate cancer and radiographic evidence of metastatic disease. Patients had to be defined by the clinician as having CRPC, typically constituting failure of combined androgen blockade with leuprolide and bicalutamide followed by antiandrogen withdrawal. With appropriate counseling with regard to treatment options, patients who opted to receive either abiraterone or enzalutamide, with an anticipated monitoring plan that included serial collections of prostate-specific antigen (PSA) readouts, were consented for serial blood collection for correlative studies. Prostate Cancer Working Group 3 (PCWG3) criteria were used to define progression. 7 A log-rank test was used to determine differences between CTC groups and the time to progression.
CTC Enumeration and Isolation
Blood from eligible patients with mCRPC were collected into CellSave (enumeration) or ethylenediaminetetraacetic acid (isolation) tubes at baseline; at weeks 4, 8, and 12 of therapy; and at the time of progression (Supporting Fig. 1 ). The standard CellSearch platform was used for enumeration. For isolation, blood was enriched for CTCs 24 hours after collection; and 7.5 mL of blood was used per test to enrich CTCs. The samples were processed on the AutoPrep system using the CellSearch CTC Profile Kit (catalog no. 7900004; Veridex, LLC). The kit enriches CTCs without the staining and permeabilization steps. To facilitate manual isolation of CTCs with a micromanipulator, samples were stained with an epithelial cell adhesion molecule (EpCAM)-positive/CD45-negative antibody cocktail for 15 minutes. Cells were then pipetted onto Petri dishes for cell settling, and individual EpCAM-positive and CD45-negative cells were isolated.
Data Analysis
RNA sequencing was performed on an Illumina HiSeq platform (Illumina, San Diego, CA). For details on mapping of RNA-seq reads, data quality assessment, gene set enrichment analysis, mutation calling, gene fusion detection, and differential gene expression analysis, please see the Supporting Methods (see online supporting information).
Cell Culture and Transfections
LNCaP cells were originally purchased from the American Type Culture Collection (ATCC) (Manassas, VA). Cells lines have undergone cell line authentication by the ATCC in the last 2 years. Enzalutamide-resistant LNCaP cell lines were independently selected in increasing amounts of enzalutamide over time in the Janssen and Jones laboratories. Cells were maintained in phenol redfree RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and then were transferred to charcoalstripped (C/S) media before luciferase and quantitative polymerase chain reaction (PCR) assays. The CCND1 expression plasmid was obtained from the Harvard PlasmidID Repository (clone HsCD00456385; Boston, MA). Cells were transfected using Lipofectamine Plus (Thermo Fisher Scientific, Springfield Township, NJ). For growth curves, LNCaP cells were transferred to C/S media 3 days before they were split and plated at a density of approximately 20,000 cells per well in 48-well plates, in quadruplicate. The next day, medium with or without dihydrotestosterone (DHT) and drugs was added to the cells. Proliferation was determined by measuring the DNA content of the cells in each well. Cells were fixed in 2% paraformaldehyde, followed by staining for 5 minutes at room temperature with 0.2 ng/mL 4 0 ,6-diamidino-2-phenylindole in phosphate-buffered saline. Then the cells were washed with phosphate-buffered saline and read on a fluorescence plate reader using 365/439 excitation/emission wavelengths. Student t tests were used to determine significant differences between DHT-treated and drugtreated populations.
For SMAD3 experiments, SMAD3 small-interfering RNA (M-020067-00-0005; purchased from GE Dharmacon, Lafayette, CO) knockdown experiments were conducted on enzalutamide-sensitive and enzalutamide-resistant The transforming growth factor b (TGFb) signaling pathway is illustrated, with genes that differed significantly between drug-sensitive and drug-resistant samples indicated. Red indicates up-regulation in drug-resistance samples; green, down-regulation in drug-resistant samples. ARKADIA indicates E3 ubiquitin-protein ligase; BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein receptor; CBP, CREB-binding protein; CDC42, cell division control protein 42 homolog; c-JUN, Jun proto-oncogene, transcription factor subunit; c-RAF, RAF proto-oncogene serine/threonine-protein kinase; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; FOXH1, forkhead box 1; GRB2, growth factor receptor-bound protein 2; GSC, goosecoid homeobox; HOXC8, homeobox C8; HPK1, hematopoietic progenitor kinase 1; IRF7, interferon regulatory factor 7; JNK1/2, c-Jun N-terminal kinases 1 and 2; MAPK, mitogenactivated protein kinase; MEK1/2, mitogen-activated protein kinase kinases 1 and 2; MIS, Mullerian-inhibiting substance; MKK, mitogen-activated protein kinase kinase; NODAL, nodal growth-differentiation factor; OAZ, ornithine decarboxylase antizine; P, protein; p38, a group of mitogen-activated protein kinases; PAI-1, plasminogen activator inhibitor-1; PIASy, protein inhibitor of activated STAT protein g; RAS, rat sarcoma; RTK, receptor tyrosine kinase; RUNX, Runt-related transcription factor; SARA, SMAD anchor for receptor activation; SKI, v-ski avian sarcoma viral oncogene homolog; SMURF1, SMAD-specific E3 ubiquitin protein ligase 1; SOS, son of sevenless; TAB1, transforming growth factor b activated kinase 1 binding protein 1; TAK1, transforming growth factor b activated kinase 1; TCF, T-cell factor; TFE3, transcription factor binding to immunoglobulin heavy constant l enhancer 3; TGIF, transforming growth factor b-induced factor; TLX2, T-cell leukemia homeobox 2; TMEPAI, transmembrane prostate androgen-induced protein; TRAF6, tumor necrosis factor receptor-associated receptor; VDR, vitamin D receptor.
LNCaP cells. Approximately 2000 cells were seeded on day 0, small-interfering RNA was added on day 1, and cellular viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (catalog no. G7571; Promega Corporation, Madison, Wis) at 24, 48, and 72 hours. Separate cell lysates were collected at 48 hours after transfection to measure knockdown efficiency using the TaqMan Gene Expression Cells-to-CT Kit (catalog no. AM1728; Thermo Fisher Scientific). Real-time PCR was performed on the QuantStudio 12K Flex Real-Time PCR System (Thermo Fisher Scientific) using SMAD3 primers (Hs00969210_m1) and CCND1 gene-specific primers (forward, CCTTCCGGTG TGAAACATCTA; reverse, GCCAACTGGTGTTTGAA AGTAG).
RESULTS
Clinical Characteristics of Study Participants and RNA-Seq Characterization of CTCs
Clinical characteristics of patients who participated in the study are described in the Supporting Materials (see online supporting information). Blood was collected from 36 patients for CTC enumeration and isolation at baseline (just before the start of therapy); at 4, 8, and 12 weeks after the start of therapy; and at the time of progression (Supporting Fig. 1 ; see online supporting information). We observed that, as reported previously, a baseline CTC count of 5 per 7.5 mL of blood was associated with a more rapid time to progression (P < .001). By using only samples from patients who had 5 CTCs per 7.5 mL of blood at baseline (18 of 36 patients enrolled in this study), EpCAM-positive, CD45-negative cells were isolated and prepared for RNA extraction. Previous studies have reported significant technical variations in low-input RNA sequencing methods as the amount of starting RNA material is reduced. 8, 9 To minimize these variations, we sequenced pools of up to 10 CTCs from individual samples. Twenty-one unique data sets from 12 different patients passed our strict RNA-seq data-quality analysis. Expression analysis of prostate cancer lineage genes (eg, AR, PSA, prostate-specific membrane antigen (PSMA), and a-methylacyl-coenzyme A racemase (AMACR)) in our CTC data sets strongly suggested that collected cells were of prostate cancer origin (Supporting Fig. 2A ; see online supporting information), and gene set enrichment analyses demonstrated considerable enrichment of a prostate cancer signature in our CTC data sets (Supporting Fig. 2B ; see online supporting information).
RNA sequencing provides single nucleotide resolution of expressed transcripts, thereby facilitating identification of mutations in protein coding regions. Our mutation analysis revealed the presence of point mutations in genes, including AR, ATRX, GNAS, FOXA1, KMT2A, speckle-type poxvirus and zinc finger protein 1 (SPOP1), and CNOT1, all of which have been detected previously in DNA samples collected from patients with CRPC (Supporting Fig. 3A ; see online supporting information). 10, 11 Both established and novel mutations were identified in AR, including deleterious frameshift and early truncation mutations in the androgenbinding domain (Supporting Fig. 3B ; see online supporting information). Similarly, our gene fusion analysis (Supporting Table 3 ; see online supporting information) revealed transmembrane protease, serine 1:estrogen regulated gene (TMPRSS2:ERG) fusion in 3 CTC samples, whereas 1 sample had a solute carrier family 45 member 3:erythroblast transformation-specific domain-containing protein (SLC45A3:ELK4) gene fusion. These fusions have been widely reported in prostate tumors. 12 Next, we analyzed the AR-V7 splice variant, which lacks the AR ligand-binding domain and whose expression has been associated with clinical resistance to antiandrogens. 13 AR-V7 was detected at various levels in 12 of 24 samples (Supporting Fig. 3B ; see online supporting information). Taken together, our RNAseq data obtained from CTCs had excellent agreement with previous genomic analyses using CRPC tissue samples.
Differential Gene Expression Analysis
We next performed differential gene expression analysis between drug-sensitive and drug-resistant CTC samples. Samples from patients who were receiving abiraterone or enzalutamide were grouped for this analysis in part to increase the evaluable sample number and also because cross-resistance to these AR signal-targeting drugs is widespread, 14, 15 suggesting that they develop resistance by common mechanisms. CTCs derived from patients who had been diagnosed with clinically progressing disease according to PCWG3 criteria 7 and had a > 50% increase in blood PSA levels compared with their previously measured levels (Fig. 1A) were classified as drug-resistant CTCs. By using these criteria, we identified 5 samples each with drug-sensitive and drug-resistant CTCs, although these samples were not paired; sensitive and resistant samples were not from the same patient (Fig. 1B) .
Our analysis revealed approximately 2100 differentially regulated genes in drug-resistant CTCs. By using Ingenuity pathway analysis (Qiagen, Germantown, MD), we identified several pathways that were altered in the drug-resistant samples (Supporting Table 4 ; see online supporting information), including an upregulation of TGFb signaling. TGFb signaling is mediated through the SMAD family of proteins, which, upon phosphorylation, translocate to the nucleus and initiate transcription programs. SMAD3 was significantly upregulated (approximately 8-fold) in the drug-resistant samples. In addition, several components of this pathway were differentially regulated (Fig. 1C) , including mitogen-activated protein kinase and activin type II receptor, highlighting a possible role of this pathway in inducing resistance to abiraterone and enzalutamide.
To test the role of TGFb signaling in resistance, we generated an enzalutamide-resistant LNCaP cell line that was maintained in the presence of 10 lM enzalutamide ( Fig. 2A) . This cell line did not harbor any AR mutations in addition to the threonine-to-alanine mutation at position 877 (T877A), which is present in LNCaP cells, including the phenylalanine-to-leucine mutation at position 876 (F876L), which has been associated with resistance to enzalutamide. 16 Next, we performed short-hairpin RNA-mediated knockdown of SMAD3 in parental and resistant LNCaP cells and measured cell viability at multiple time points. Our knockdown assay revealed significant downregulation of SMAD3 transcripts in both parental and resistant LNCaP cell lines (Fig. 2B) , which led to a significant loss in viability of resistant cells, whereas the parental cell line was largely unaffected (Fig. 2C) .
Our differential gene expression analysis also revealed upregulation of cyclin-D1 (CCND1) in drugresistant CTCs (Fig. 3A) . To test the ability of CCND1 to mediate enzalutamide resistance, we transiently overexpressed it in LNCaP cells and observed that, compared with parental cells, CCND1 overexpression caused increased proliferation, comparable to growth in the presence of DHT, and, most important, abolished sensitivity to enzalutamide (Fig. 3B) . Cyclin-dependent kinase (CDK)4/6 inhibitors are known to inhibit the growth of cells with alterations in the CCND1 pathway. 17 It is striking that addition of the CDK4/CDK6 inhibitor palbociclib (PD0332291) or ribociclib (LEE011) significantly inhibited the proliferation of both parental and CCND1 overexpressing LNCaP cells. It is noteworthy that adding palbociclib to enzalutamide in parental cells did not further decrease their growth, whereas it was able to significantly inhibit the enzalutamide-resistant growth of CCND1 overexpressing cells. A second, independent, enzalutamide-resistant LNCaP cell line was developed. This line also did not harbor any point mutations in the AR gene in addition to the pre-existing T877A mutation, but it did exhibit the significant overexpression of CCND1 (Fig. 3A) . Treatment of this cell line with palbociclib or ribociclib significantly inhibited its growth, suggesting that CCND1 was a driver in this enzalutamideresistant line (Fig. 3C) .
DISCUSSION
Here, for the first time, we report RNA-seq of prostate cancer CTCs obtained from sequential samples of patients who were beginning treatment with abiraterone or enzalutamide, and we identify the potential mechanisms of resistance to these agents, which target AR signaling. Several studies have reported RNA-seq of putative CTCs from prostate cancer, but none have used the CellSearch platform for initial purification of cells, nor have they analyzed sequential samples obtained from patients during treatment. [18] [19] [20] The most detailed study to date used the CTC-iChip to magnetically deplete normal hematopoietic cells from whole-blood specimens, then manually isolated 221 single-candidate prostate CTCs, defined by the ). An asterisk indicates P <.05 (2-tailed Student t test; n 5 4). (C) Enzalutamide (Enza)-resistant LNCaP cells were distributed in 48-well plates, and the indicated drugs were added. Relative growth at day 6 is illustrated. Addition of the CDK4/CDK6 inhibitors palbociclib (PD0332291) and ribociclib (LEE011) led to significant cell death compared with controls (100 nM Enza). An asterisk indicates P <.05 (2-tailed Student t test; n 5 4).
expression of EpCAM and cadherin-11 and the absence of CD45, from 18 patients with metastatic prostate cancer and 4 patients with localized prostate cancer. 19 Those investigators reported that 60% of individual cells had RNA of sufficient quality for amplification and nextgeneration RNA sequencing. In our initial studies, we identified even fewer individual CTCs that had RNA of sufficient quality for RNA-seq, which prompted us to use pools of CTCs for analysis.
One advantage of sequencing RNA compared with DNA is the ability to detect both mutations and changes in signaling pathways that would not be evident from mutations alone. We detected mutations that have been extensively documented in prostate cancer, including AR and SPOP mutations and the TMPRSS2:ERG fusion. 21 We detected several noteworthy AR mutations that have not been documented previously in prostate cancer. Several are located in the AF-1 region of the amino-terminal domain, which is known to be highly mutated in prostate cancer 22 ; and another, an arginine-to-glycine mutation at position 847 (R847G), appears to be functional, because it has been demonstrated that mutations of this residue disrupt the ubiquitination and degradation of AR. 23 We also detected deleterious frameshift and early truncation mutations in the androgen-binding domain of AR that could offer escape mechanisms from AR-targeted therapies in the same way as AR splice variants.
Our pathway analyses identified TGFb signaling as a major difference between unpaired samples of drugsensitive and drug-resistant disease. Although it was not specifically investigated, Miyamoto et al also observed that TGFb signaling was enriched in CRPC CTCs compared with primary tissue. 19 Signaling through SMAD proteins, including SMAD3, has long been known to be involved in prostate cancer initiation and progression. 24 Whether increased SMAD3 signaling simply reflects a shift to a metastatic state or represents a true mechanism of resistance to AR-targeted therapies warrants further investigation.
We also observed that CCND1 pathway signaling was enriched in drug-resistant samples. We also made the important observation that CDK4/CDK6 inhibitors were effective at inhibiting the enzalutamide-resistant growth of LNCaP cells. The CCND1 pathway is commonly dysregulated in cancers 25 and has long been thought to contribute to prostate cancer progression. 26 We interrogated the publicly available Neuroendocrine Prostate Cancer data set 27 on the cBioPortal for Cancer Genomics for alterations in CCND1 pathway genes (Supporting Fig. 4 ; see online supporting information). This data set is derived from patient samples that are very similar to ours-samples from heavily pretreated patients who had CRPC. CCND1, CCND2, CCND3, CDK4, and CDK6 were amplified or overexpressed at the transcript level in 27% to 53% of the samples, and most were enriched in the neuroendocrine samples compared with the adenocarcinoma CRPC samples. Retinoblastoma gene loss, which could render CDK4/CDK6 inhibitors ineffective, because it is downstream of the CDKs in the signaling pathway, only occurred in 7% of samples. Others have recently discussed a role for CDK4/CDK6 inhibitors in prostate cancer, 28 and several clinical trials are now testing CDK4/ CDK6 inhibitors in metastatic prostate cancer (clinicaltrials.gov identifiers NCT02494921, NCT02555189, NCT02059213, NCT02905318). Our data suggest that such inhibitors will have an important role in cancers that are resistant to AR-targeted agents.
Our study also challenges findings from previous studies in CRPC. We did not detect a significant increase in AR-V7 levels between drug-sensitive and drug-resistant samples, nor did high baseline levels of AR-V7 necessarily portend a poor response to drug. Indeed, the 4 patients who had highest baseline levels of AR-V7 all responded initially to abiraterone or enzalutamide, although all developed resistance within 1 year of starting the drug. Despite evidence that AR-V7 expression is a negative predictive marker for AR-targeted therapies, 13 our data, combined with those from other studies, 19, 29 suggest that it is not always accurate and that some patients who express AR-V7 still may benefit from abiraterone and enzalutamide. Furthermore, it suggests that mechanisms in addition to AR splice variant expression could contribute to resistance to these agents. One of those proposed mechanisms is the upregulation of the glucocorticoid receptor to replace AR signaling. However, we and others 19 did not observe significant upregulation of glucocorticoid receptor in resistant samples.
Like Miyamoto et al, we observed significant increases in the expression of Wnt transcripts (WNT7B and WNT5A) and genes associated with canonical Wnt signaling, including FZD4 and LEF1, in resistant samples. However, we did not observe increased expression of the noncanonical Wnt pathway targets "cell division control protein 42 homolog" (CDC42), RHOA, or RAC; nor was the noncanonical Wnt pathway identified as enriched in drug-resistant samples in our pathway analyses. Thus, the extent and clinical relevance of Wnt pathway activation in drug-resistant prostate cancers remain to be determined.
Our current study has several limitations, and the first is the size of our sample. Whereas we enrolled 36
Original Article patients who had baseline draws obtained between April 2014 and December 2015, 13 of those patients still have yet to progress, and 3 others went off protocol. Because 7 patients had no detectable CTCs at baseline and there were several technical failures to amplify RNA, we were able to make comparisons between only 5 unpaired drugsensitive and drug-resistant samples; but paired analysis would have been preferred, because analysis in unpaired samples can introduce inter-patient heterogeneity. Differential gene expression could be the result of differences in tumor biology caused by variations in patients, and not in drug exposure. Another limitation of the study is that we used using only EpCAM-positive cells. It is very likely that important CTCs were missed, and perhaps our results reflect only changes in cancers that had strong epithelial phenotypes: presumably those that remained adenocarcinomas. It would be very interesting to repeat this study using an alternative CTC isolation platformperhaps one that is independent of EpCAM for capture and uses other markers to define CTCs, such as the Epic platform. 30 Another limitation is potential variability in the clinical definition of resistance. Although we used PCWG3 criteria, progression is not always the same from patient to patient, which could mean that tumor heterogeneity was not fully captured in this study. Nonetheless, our study did identify several potential mechanisms of resistance that were validated in cell culture models of enzalutamide resistance. Although SMAD3 may be difficult to target, cells with increased CCND1 pathway activation are known to be sensitive to CDK4/CDK6 inhibitors, 17 and ongoing clinical trials will help to test the hypothesis that these drugs will inhibit the growth of abiraterone/enzalutamide-resistant CRPC. The current findings should strongly encourage additional translational/correlative studies to validate these hypothesisgenerating results.
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